# Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer

> **NCT07457359** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 18 (estimated)

## Conditions studied

- TNBC, Triple Negative Breast Cancer

## Interventions

- **RADIATION:** SBRT
- **DRUG:** Toripalimab (anti-PD-1 antibody)
- **DRUG:** Chemotherapy switch

## Key facts

- **NCT ID:** NCT07457359
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-04
- **Primary completion:** 2028-01-04
- **Final completion:** 2029-01-04
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07457359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07457359, "Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07457359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*